Reuters logo
BRIEF-Ignyta provides update on entrectinib and RXDX-105 at the ESMO 2017 Congress
September 11, 2017 / 12:25 PM / 3 months ago

BRIEF-Ignyta provides update on entrectinib and RXDX-105 at the ESMO 2017 Congress

Sept 11 (Reuters) - Ignyta Inc

* Ignyta provides update on entrectinib and RXDX-105 at the esmo 2017 congress

* Ignyta -‍confirms completion of enrollment of efficacy data sets for both NTRK tissue-agnostic cohort,ros1 nsclc cohort to support dual NDA submissions in 2018​

* Ignyta Inc - ‍RXDX-105 phase 1b study will be concluded with no further enrollment; those currently receiving treatment will remain on study​

* Ignyta Inc - ‍will continue discussing RXDX-105 with potential partners and will provide an update on the program in first half of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below